MA26973A1 - Activateurs glucokinase isoindolin-1-one - Google Patents

Activateurs glucokinase isoindolin-1-one

Info

Publication number
MA26973A1
MA26973A1 MA27197A MA27197A MA26973A1 MA 26973 A1 MA26973 A1 MA 26973A1 MA 27197 A MA27197 A MA 27197A MA 27197 A MA27197 A MA 27197A MA 26973 A1 MA26973 A1 MA 26973A1
Authority
MA
Morocco
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
MA27197A
Other languages
English (en)
French (fr)
Inventor
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26973A1 publication Critical patent/MA26973A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
MA27197A 2000-12-13 2003-06-12 Activateurs glucokinase isoindolin-1-one MA26973A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13

Publications (1)

Publication Number Publication Date
MA26973A1 true MA26973A1 (fr) 2004-12-20

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27197A MA26973A1 (fr) 2000-12-13 2003-06-12 Activateurs glucokinase isoindolin-1-one

Country Status (35)

Country Link
US (1) US6482951B2 (enExample)
EP (1) EP1349856B1 (enExample)
JP (1) JP4021766B2 (enExample)
KR (1) KR100520651B1 (enExample)
CN (1) CN1247574C (enExample)
AT (1) ATE297922T1 (enExample)
AU (2) AU2002238415B2 (enExample)
BG (1) BG107903A (enExample)
BR (1) BR0116169A (enExample)
CA (1) CA2430579C (enExample)
CY (1) CY1105587T1 (enExample)
CZ (1) CZ20031882A3 (enExample)
DE (1) DE60111570T2 (enExample)
DK (1) DK1349856T3 (enExample)
EG (1) EG24358A (enExample)
ES (1) ES2243578T3 (enExample)
HR (1) HRP20030450B1 (enExample)
HU (1) HUP0400587A3 (enExample)
IL (2) IL156264A0 (enExample)
MA (1) MA26973A1 (enExample)
MX (1) MXPA03005170A (enExample)
MY (1) MY136741A (enExample)
NO (1) NO325810B1 (enExample)
NZ (1) NZ526236A (enExample)
PA (1) PA8534601A1 (enExample)
PE (1) PE20020593A1 (enExample)
PL (1) PL366006A1 (enExample)
PT (1) PT1349856E (enExample)
RS (1) RS50933B (enExample)
RU (1) RU2249590C2 (enExample)
SI (1) SI1349856T1 (enExample)
SK (1) SK8732003A3 (enExample)
TW (1) TWI294876B (enExample)
UY (1) UY27069A1 (enExample)
WO (1) WO2002048106A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト 2型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換(チアゾール−2−イル)−アミドまたはスルホンアミド
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
ATE524479T1 (de) 2004-04-02 2011-09-15 Novartis Ag Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
JP2007530631A (ja) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
BRPI0615236A2 (pt) * 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007053657A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
JP2009518286A (ja) * 2005-11-01 2009-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしてのジヒドロイソインドロン
WO2007053503A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
AU2008225613B2 (en) * 2007-03-07 2012-06-14 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
CN101925596B (zh) * 2008-01-24 2014-05-28 默克专利有限公司 用于治疗糖尿病的β-氨基酸衍生物
MX2010011778A (es) 2008-04-28 2010-11-30 Kyorin Seiyaku Kk Derivados de ciclopentil acrilamida.
MY152749A (en) * 2008-05-16 2014-11-28 Takeda California Inc Pyrazole and fused pyrazole glucokinase activators
CN102216276A (zh) * 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN107090016A (zh) 2011-03-01 2017-08-25 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
WO2014191340A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
RU2021109549A (ru) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたn−(インドール−2−カルボニル)−グリシンアミド類および誘導体
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
MXPA02010746A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de la glucocinasa que contienen hidantoina.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer

Also Published As

Publication number Publication date
NO20032674L (no) 2003-06-12
DK1349856T3 (da) 2005-10-17
IL156264A (en) 2010-11-30
PE20020593A1 (es) 2002-07-06
YU47703A (sh) 2006-05-25
WO2002048106A2 (en) 2002-06-20
MY136741A (en) 2008-11-28
UY27069A1 (es) 2002-07-31
EG24358A (en) 2009-03-04
EP1349856B1 (en) 2005-06-15
HRP20030450B1 (en) 2006-02-28
PL366006A1 (en) 2005-01-24
KR20030064817A (ko) 2003-08-02
DE60111570D1 (de) 2005-07-21
CA2430579A1 (en) 2002-06-20
US20020082260A1 (en) 2002-06-27
CY1105587T1 (el) 2010-07-28
AU3841502A (en) 2002-06-24
RU2249590C2 (ru) 2005-04-10
HRP20030450A2 (en) 2005-04-30
US6482951B2 (en) 2002-11-19
SK8732003A3 (en) 2004-04-06
BG107903A (bg) 2004-02-27
BR0116169A (pt) 2003-12-23
RS50933B (sr) 2010-08-31
PA8534601A1 (es) 2002-08-26
NZ526236A (en) 2004-12-24
ATE297922T1 (de) 2005-07-15
ES2243578T3 (es) 2005-12-01
HUP0400587A2 (hu) 2004-06-28
CN1247574C (zh) 2006-03-29
MXPA03005170A (es) 2003-09-22
EP1349856A2 (en) 2003-10-08
JP2004521095A (ja) 2004-07-15
HK1063314A1 (en) 2004-12-24
WO2002048106A3 (en) 2002-11-28
CZ20031882A3 (cs) 2003-12-17
TWI294876B (en) 2008-03-21
CN1481382A (zh) 2004-03-10
KR100520651B1 (ko) 2005-10-11
DE60111570T2 (de) 2006-05-11
NO20032674D0 (no) 2003-06-12
PT1349856E (pt) 2005-09-30
NO325810B1 (no) 2008-07-21
CA2430579C (en) 2010-01-26
SI1349856T1 (en) 2005-10-31
IL156264A0 (en) 2004-01-04
JP4021766B2 (ja) 2007-12-12
HUP0400587A3 (en) 2011-03-28
AU2002238415B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
MA26973A1 (fr) Activateurs glucokinase isoindolin-1-one
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
HRP20050287A2 (en) Indole-3-carboxamides as glucokinase (gk) activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
DE60231295D1 (de) R und ppar modulatoren
ATE461217T1 (de) Glp-1-verbindungen
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE60031248D1 (de) Elektroaktive pore
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60134251D1 (de) Verwendung von glp-2-peptiden
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
CY1109972T1 (el) Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
EE200000446A (et) Follikulaarsete lümfoomide ravi lümfotoksiini (LT) raja inhibiitorite abil
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
TW200613343A (en) Novel prepolymers for improved surface modification of contact lenses
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR051035A1 (es) Uso de epotilonas en el tratamiento de metastasis en hueso
MD1919G2 (ro) Remediu medicamentos
DK200000263Y6 (da) Bandage til behandling af tryksår, liggesår og lignede lidelser.